Transcriptional Expression of SLC2A3 and SDHA Predicts the Risk of Local Tumor Recurrence in Patients with Head and Neck Squamous Cell Carcinomas Treated Primarily with Radiotherapy or Chemoradiotherapy

SLC2A3 和 SDHA 的转录表达可预测接受放射治疗或放化疗的头颈部鳞状细胞癌患者的局部肿瘤复发风险

阅读:2

Abstract

Reprogramming of metabolic pathways is crucial to guarantee the bioenergetic and biosynthetic demands of rapidly proliferating cancer cells and might be related to treatment resistance. We have previously demonstrated the deregulation of the succinate pathway in head and neck squamous cell carcinoma (HNSCC) and its potential as a diagnostic and prognostic marker. Now we aim to identify biomarkers of resistance to radiotherapy (RT) by analyzing the expression of genes related to the succinate pathway and nutrient flux across the cell membrane. We determined the transcriptional expression of succinate receptor 1 (SUCNR1), succinate dehydrogenase A (SDHA), and the solute carrier (SLC) superfamily transporters responsible for the influx or efflux of a wide variety of nutrients (SLC2A3 and SLC16A3) in tumoral tissue from 120 HNSCC patients treated with RT or chemoradiotherapy (CRT). Our results indicated that the transcriptional expression of the glucose transporter SLC2A3 together with SDHA had the best predictive capacity for local response after treatment with RT or CRT. High SLC2A3 and SDHA expression predicted poor outcomes after RT or CRT, with these patients having a 4.2 times higher risk of local recurrence compared to the rest of the patients. These results might indicate that tumors that shifted toward a higher glucose influx and a higher oxidation of succinate via mitochondrial complex II present an ideal environment for radioresistance development. Patients with a high transcriptional expression of both SLC2A3 and SDHA had a significantly higher risk of local recurrence after treatment with RT or CRT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。